REG - Scancell Holdings - Notice of AGM

Scancell HoldingsAnnouncement

03/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251003:nRSC8829Ba&default-theme=true

RNS Number : 8829B  Scancell Holdings Plc  03 October 2025

3 October 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Notice of Annual General Meeting

 

Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and
Moditope® active immunotherapies to treat cancer, announces that the
Company's Annual Report and Accounts for the year ended 30 April 2025 and
Notice of Annual General Meeting ("AGM") will be sent to shareholders shortly.

The Annual Report and Accounts for the year ended 30 April 2025 are available
on the Company's website at
https://www.scancell.co.uk/investors/financial-info
(https://www.scancell.co.uk/investors/financial-info) , and the Notice of AGM
will be made available today at https://scancell.co.uk/documents-presentations
(https://scancell.co.uk/documents-presentations/) under the section titled
Annual General Meeting.

The AGM will be held at 3.00pm GMT at the offices of Cooley (UK) LLP at 22
Bishopsgate, London, EC2N 4BQ on Thursday 30th October 2025.

After the AGM, Scancell's senior management team will be presenting the final
results for the year ended 30 April 2025 followed by a Q&A session, and
all shareholders are invited to attend in person.

-ENDS-

Scancell (LSE:SCLP; www.scancell.co.uk (http://www.scancell.co.uk) ) is a
clinical stage biotechnology company developing targeted off-the-shelf active
immunotherapies, to generate safe and long-lasting tumour-specific immunity
for a cancer-free future. iSCIB1+, the lead product from their DNA
ImmunoBody® platform has demonstrated safe, durable and clinically meaningful
benefit as a monotherapy as well as additional benefit when combined with
checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the lead
peptide immunotherapy from their Moditope® platform, is being investigated in
a Phase 2 study in a broad range of solid tumours. In addition, Scancell's
wholly owned subsidiary, GlyMab Therapeutics Ltd., has been established with
the intention to hold and develop an exciting early-stage pipeline of high
affinity GlyMab® antibodies targeting tumour specific glycans, two of which
already have been licensed and are being developed by Genmab A/S, an
international biotechnology company and global leader in the antibody
therapeutics space.

For more information please contact:

 Scancell Holdings plc                                   +44 (0) 20 3709 5700
 Phil L'Huillier, CEO
 Sath Nirmalananthan, CFO

 Panmure Liberum (Nominated Adviser and Joint Broker)    +44 (0) 20 7886 2500
 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                          +44 (0) 20 3705 9330

 David Wilson, Claes Spang

 Investor and media relations                            +44 (0) 20 7483 284853

 Mary-Ann Chang                                          MaryAnnChang@scancell.co.uk

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAMTBITMTAMBFA